Modeling in vivo interactions of engineered nanoparticles in the pulmonary alveolar lining fluid
File(s)
Published version
Author(s)
Type
Journal Article
Abstract
Increasing use of engineered nanomaterials (ENMs) in consumer products may result in widespread human inhalation exposures. Due to their high surface area per unit mass, inhaled ENMs interact with multiple components of the pulmonary system, and these interactions affect their ultimate fate in the body. Modeling of ENM transport and clearance in vivo has traditionally treated tissues as well-mixed compartments, without consideration of nanoscale interaction and transformation mechanisms. ENM agglomeration, dissolution and transport, along with adsorption of biomolecules, such as surfactant lipids and proteins, cause irreversible changes to ENM morphology and surface properties. The model presented in this article quantifies ENM transformation and transport in the alveolar air to liquid interface and estimates eventual alveolar cell dosimetry. This formulation brings together established concepts from colloidal and surface science, physics, and biochemistry to provide a stochastic framework capable of capturing essential in vivo processes in the pulmonary alveolar lining layer. The model has been implemented for in vitro solutions with parameters estimated from relevant published in vitro measurements and has been extended here to in vivo systems simulating human inhalation exposures. Applications are presented for four different ENMs, and relevant kinetic rates are estimated, demonstrating an approach for improving human in vivo pulmonary dosimetry.
Date Issued
2015-07-22
Date Acceptance
2015-07-09
Citation
Nanomaterials, 2015, 5 (3), pp.1223-1249
ISSN
2079-4991
Publisher
MDPI
Start Page
1223
End Page
1249
Journal / Book Title
Nanomaterials
Volume
5
Issue
3
Copyright Statement
© 2015 The Authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
License URL
Sponsor
Asthma UK
Asthma UK
GlaxoSmithKline Services Unlimited
Department of Health
Imperial College Trust
Wellcome Trust
Imperial College Trust
Imperial College Trust
Asthma UK
Byk Gulden
GlaxoSmithKline Services Unlimited
Scios Inc
Novartis Pharmaceuticals UK Limited
Novartis Pharmaceuticals UK Limited
Novartis Pharmaceuticals UK Limited
Asthmatx, Inc
National Institutes of Health
University of Medicine and Dentistry of New Jersey/School of Public Health
Arriva Pharmaceuticals Inc
Department of Health
Baxter Healthcare SA
Syngenta Crop Protection AG
Unilever UK Central Resources Ltd
Royal Brompton & Harefield Hospital Charitable Fund
Colt Foundation
Biotechnology and Biological Sciences Research Council (BBSRC)
Engineering & Physical Science Research Council (EPSRC)
Imperial College Trust
Medical Research Council (MRC)
Commission of the European Communities
Imperial College Trust
Wellcome Trust
Natural Environment Research Council (NERC)
Pfizer Limited
Novartis Pharmaceuticals UK Limited
Unilever UK Central Resources Ltd
Natural History Museum
Wellcome Trust
Engineering & Physical Science Research Council (EPSRC)
Imperial College Trust
Kaust UK Ltd
Asthma UK
Department for Environment, Food and Rural Affairs
Medical Research Council (MRC)
Medical Research Council (MRC)
Imperial College Trust
Commission of the European Communities
Novartis Pharma Ag
AstraZeneca UK Limited
FEI Company
The Royal Society
Royal Brompton & Harefield NHS Foundation Trust
Engineering & Physical Science Research Council (EPSRC)
National Institute for Health Research
Royal Brompton & Harefield NHS Foundation Trust
British Heart Foundation
Kaust UK Ltd
Commission of the European Communities
The Leverhulme Trust
Royal Brompton & Harefield NHS Foundation Trust
Medical Research Council (MRC)
Commission of the European Communities
Commission of the European Communities
Asthma UK
Engineering & Physical Science Research Council (EPSRC)
Royal Brompton & Harefield NHS Foundation Trust
UCB Celltech Ltd
Engineering & Physical Science Research Council (EPSRC)
Medical Research Council (MRC)
BP International Limited
Kaust
Technology Strategy Board
Merck Sharp & Dohme Ltd.
Commission of the European Communities
British Heart Foundation
Commission of the European Communities
British Lung Foundation
Wellcome Trust
Dunhill Medical Trust
Commission of the European Communities
Wellcome Trust
Vectura Limited
Shell Global Solutions International BV
Imperial College Trust
National Institute for Health Research
Grant Number
01/-61
03/079
N/A
TOX5/16
N/A
059857/Z/99/Z
N/A
N/A
04/063
PN1220BG
ARIFLO SB207499/ 181
N/A
CIGE0251A04E2
CIGE02501011E3
CIGE025 A2306
Protocol 0903-27
1 RO1 HL69155-01
#02-9
DR T TETLEY
TOX5/16
PN1230BH
DR T TETLEY
4800017750
C/05/12
JD/303
BB/D018617/1
EP/E500641/1
N/A
G0600512
LSHB-CT-2006-018996
DHTAC_P12276
083905/Z/07/Z
NE/E009166/1
Dr T Tetley
CQAB149B2334
CH-2008-0228
DHTAT_P19908
085935/Z/08/Z
EP/F05677X/1
DHTAC_P17217
N/A
08/041
PO. no 309601
G0700900
G0700926
DHTAC_P20775
214478
2009AT003B
AZ154160
N9-1501
MMACM48F48144
BRU 6578/39020
EP/H045090/1
NF-SI-0509-10080
2009AT008B
PG/10/80/28605
N/A
ERC-2010-StG-20091028
F/07 058/BT
B1005
G1001367
270194
115010
10/066
N/A
BRU 6535
U BIOPRED SUPPORT FUNDING
EP/K503381/1
MR/L012677/1
Order No. 75195/ICAM10 (IC)
N/A
TSB
8101001672
PIEF-GA-2013-627049
PG/14/27/30679
PIIF-GA-2013-624475
RG14-10
105603/Z/14/Z
R368/0714
643607
097347/C/11/Z
n/a
PT61050 / PO4550133349
n/a
NF-SI-0515-10016
Subjects
Science & Technology
Technology
Nanoscience & Nanotechnology
Materials Science, Multidisciplinary
Science & Technology - Other Topics
Materials Science
nanoparticles
surfactant
agglomeration
adsorption
lipid vesicles
surfactant proteins
Monte Carlo
COATED SILVER NANOPARTICLES
SUPPORTED LIPID-BILAYERS
ULTRAFINE PARTICLES
PROTEIN ADSORPTION
CELL-INTERACTIONS
SURFACTANT
KINETICS
LUNG
MECHANISM
DIFFUSION
Publication Status
Published